National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.
National trends in spending on and use of oral oncologics, first quarter 2006 through third quarter 2011.
复制标题
DOI：
10.1377/hlthaff.2014.0001
复制
发表时间：
2014-10
期刊：
影响因子：
--
通讯作者：
Bhatta SS
中科院分区：
文献类型：
--
作者：
Conti RM;Fein AJ;Bhatta SS
口服处方药是一种越来越重要的癌症治疗选择。然而，同期美国在抗癌药物（称为口服肿瘤药）上的支出趋势尚未得到描述。使用全国代表性的数据，我们描述了2006年第一季度和2011年第三季度之间47种口腔肿瘤药物的全国支出和使用趋势。按2012年美元计算，全国平均每季度在口腔肿瘤学上的支出增加了37%，从9.403亿美元增加到14亿美元，这是一个重大变化。在同一时间段内，口腔肿瘤药物的平均季度使用量以显著的速度增长，但比支出（10%）慢。在这一更广泛的趋势中，观察到口腔肿瘤学类别之间的支出差异。高水平和增加的支出和使用集中在新的品牌和专利保护的口服肿瘤药物，包括用于治疗慢性粒细胞白血病的第二代酪氨酸激酶抑制剂。在研究期间失去专利保护的口腔肿瘤药物中观察到支出减少但使用增加，并且可以以通用形式提供，包括用于治疗乳腺癌和前列腺癌的激素疗法。新的和受专利保护的口腔肿瘤药物的支出以及相关的价格上涨是支出增加的重要驱动因素。
Oral prescription drugs are an increasingly important treatment option for cancer. Yet contemporaneous US trends in spending on anticancer drugs known as oral oncologics have not been described. Using nationally representative data, we describe trends in national spending on and use of forty-seven oral oncologics between the first quarter of 2006 and the third quarter of 2011. Average quarterly national spending on oral oncologics increased 37 percent, from $940.3 million to $1.4 billion in 2012 dollars, a significant change. Average quarterly use of oral oncologics in the same time period measured in extended units increased at a significant pace but more slowly than spending (10 percent). Within this broader trend, differences in spending among categories of oral oncologics were observed. High levels of and increases in both spending and use were concentrated among new brand-name and patent-protected oral oncologics, including second-generation tyrosine kinase inhibitors used to treat chronic myelogenous leukemia. Decreased spending but increased use was observed among oral oncologics that lost patent protection during the study period and were available in generic form, including hormonal therapies used to treat breast and prostate cancers. Spending on new and patent-protected oral oncologics and associated price increases are significant drivers of increased spending.